A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Im… (NCT03445559) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging
United States58 participantsStarted 2018-04-09
Plain-language summary
The primary aim of this study is to determine whether a multi-modal, physician-focused behavioral intervention can improve facility-level guideline-concordant utilization of prostate cancer staging imaging. Other aims of this study include to use mixed methods to explore physician influence on guideline-concordant imaging and to determine the cost and cost impact of a physician-focused behavioral intervention to improve guideline-concordant prostate cancer imaging.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Provider Criteria:
* Urology Chiefs and attending urologists employed through the VA (full time, part time) at one of the 10 participating sites
* Physician Assistants and Nurse Practitioners employed through the VA at one of the 10 participating sites that work in the respective urology clinics
* Providers may be any gender or race/ethnicity
Qualitative portion only:
* Urology Chiefs and/or frontline staff physicians
* participating PAs \& NPs having cared for at least 5 men with incident prostate cancer within the previous 6 months
* Patients will not be directly recruited into the study.
* The investigators have obtained a waiver of HIPAA authorization and informed consent to analyze electronic health records of patients that are diagnosed with ICD-9 code 185 or ICD-10 code C61 during the study period at the 10 participating sites.
Exclusion Criteria:
Provider Criteria:
* Urology Residents will be excluded.
Patients
* Patients will be excluded if they have a history of prior malignancy
* Are over the age of 85
* Diagnosed at autopsy or by death certificate
* Died within 3 months of diagnosis
* Not having data on at least one of the following:
* PSA
* clinical stage
* Gleason score
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates
Timeframe: Through study completion, an average of 4 years
2
Facility-level Appropriate Prostate Cancer Bone Scan Imaging Rates
Timeframe: Through study completion, an average of 4 years